Microsatellite-Stable Colorectal Cancer (MSS CRC) Shows Enrichment for Loss of Neoantigenic Mutations (NAMs) Compared to CRC with Microsatellite Instability (MSI)

被引：0
|
作者：
Nadhamuni, V. Srirangam [1 ]
Lakatos, E. [1 ]
Househam, J. [1 ]
Heide, T. [2 ]
Cresswell, G. [2 ]
Spiteri, I. [2 ]
Mossner, M. [1 ]
Kimberley, C. [1 ]
Ortiz, L. Zapata [2 ]
James, C. [2 ]
Lynn, C. [2 ]
Berner, A. [1 ]
Costa, H. [3 ]
Mitchinson, M. [3 ]
Jansen, M. [3 ]
Caravagna, G. [2 ,4 ]
Rodriguez-Justo, M. [3 ]
Shibata, D. [5 ]
Bridgewater, J. [3 ]
Baker, A-M [1 ]
Sottoriva, A. [2 ]
Graham, T. [1 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, London, England
[2] Inst Canc Res, London, England
[3] UCL, London, England
[4] Univ Trieste, Trieste, Italy
[5] Univ Southern Calif, Los Angeles, CA 90007 USA
来源：
JOURNAL OF PATHOLOGY | 2021年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
    Diaz, Luis A.
    Marabelle, Aurelien
    Delord, Jean-Pierre
    Shapira-Frommer, Ronnie
    Geva, Ravit
    Peled, Nir
    Kim, Tae Won
    Andre, Thierry
    Van Cutsenn, Eric
    Guimbaud, Rosine
    Jaeger, Dirk
    Elez, Elena
    Yoshino, Takayuki
    Joe, Andrew K.
    Lam, Baohoang
    Gause, Christine K.
    Pruitt, Scott Knowles
    Kang, S. Peter
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Durvalumab plus monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
    Cho, M.
    Bendell, J. C.
    Han, S-W.
    Naidoo, J.
    Lieu, C.
    Carneiro, B. A.
    Varga, E.
    Li, X.
    Kourtesis, P.
    Abdullah, S. E.
    Patel, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC).
    Leal, Alexis Diane
    Blatchford, Patrick Jud
    Kim, Sunnie S.
    Lentz, Robert William
    Kemme, Douglas Jerome
    Russen, McKenna
    Friedrich, Tyler
    Mathew, Lynn
    Hoyer, Robert John
    Kono, Scott Arthur
    Baiyee Toegel, Emily
    Bagby, Stacey M.
    Dominguez, Adrian
    Davis, S. Lindsey
    Pitts, Todd
    Lieu, Christopher Hanyoung
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 229 - 229
  • [4] Microsatellite instability (MSI-H) in hyperplastic polyposis (HPP) associated colorectal cancer (CRC) provides evidence for the serrated CRC pathway
    Lockett, M
    Smale, W
    Lloyd, J
    Burke, S
    Pack, K
    Atkin, W
    Tomlinson, I
    Talbot, I
    GASTROENTEROLOGY, 2002, 122 (04) : A119 - A119
  • [5] Immunohistochemical evaluation of possible therapeutic targets in colorectal carcinoma (CRC) with microsatellite instability (MSI)
    Ardeleanu, R.
    Micu, G.
    Nichita, L.
    Raduta, D.
    Filip, M.
    Maria-Alexandra, M.
    Rimbas, M.
    Popp, C.
    VIRCHOWS ARCHIV, 2021, 479 : S208 - S208
  • [6] Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable ( MSS) colorectal cancer (CRC)
    Christenson, Eric S.
    Wala, Jeremiah A.
    Parkinson, Rose
    Collins, Natalie B.
    Jakubowski, Christopher
    Lin, Jea-Ren
    Wang, Hao
    Ho, Won Jin
    Chan, Sabrina
    Klein, Rachel
    Cetasaan, Yvette
    Johnson, Emma
    Berg, Maureen
    Meyerhardt, Jeffrey
    Schlechter, Benjamin
    Singh, Harshabad
    Sorger, Peter K.
    Giannakis, Marios
    Azad, Nilofer
    CANCER RESEARCH, 2024, 84 (07)
  • [7] Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype
    Pappan, Kirk
    Mayhew, Gregory
    Shepherd, Jonathan
    Guo, Yuelong
    Beebe, Kirk
    Eisner, Joel
    Milburn, Michael
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Humanized patient -derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)
    Capasso, Anna
    Lang, Julie
    Pitts, Todd M.
    Lieu, Christopher H.
    Kopetz, Scott
    Davis, Sarah L.
    Jordan, Kimberly
    Bagby, Stacey M.
    Messersmith, Wells A.
    Pelanda, Roberta
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [9] Microsatellite instability in human colorectal cancer (CRC): Effect of EGFR overexpression
    Aloulou, Nijez
    Chaumette, Marie-Therese
    Sekour, Amel
    Leroy, Karen
    Abolhassani, Mohammad
    Sobhani, Iradj
    GASTROENTEROLOGY, 2006, 130 (04) : A717 - A718
  • [10] Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
    Diamond, J. R.
    Standifer, N.
    Ascierto, M. L.
    Morehouse, C.
    Ghadially, H.
    Canales, J. Rodriguez
    Rebelatto, M. C.
    Naidoo, J.
    Mazzarella, L.
    Patel, S.
    Flor Oncala, M. J.
    Alonso Gordoa, T.
    Wang, D.
    Song, X.
    Jones, D. C.
    Li, X.
    Marshall, S.
    Abdullah, S.
    Jure-Kunkel, M.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2018, 29
12345